328 related articles for article (PubMed ID: 30850485)
1. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
6. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Wickstroem K; Karlsson J; Ellingsen C; Cruciani V; Kristian A; Hagemann UB; Bjerke RM; Ryan OB; Linden L; Mumberg D; Brands M; Cuthbertson A
Pharmaceuticals (Basel); 2019 Oct; 12(4):. PubMed ID: 31618864
[TBL] [Abstract][Full Text] [Related]
8. A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Zitzmann-Kolbe S; Kristian A; Zopf D; Kamfenkel C; Politz O; Ellingsen C; Hilbig J; Juul MU; Fonslet J; Nielsen CH; Schatz CA; Bjerke RM; Cuthbertson AS; Mumberg D; Hagemann UB
Mol Cancer Ther; 2023 Sep; 22(9):1073-1086. PubMed ID: 37365121
[TBL] [Abstract][Full Text] [Related]
9.
Broer LN; Knapen DG; Suurs FV; Moen I; Giesen D; Waaijer SJH; Indrevoll B; Ellingsen C; Kristian A; Cuthbertson AS; de Groot DA; Cole PE; de Vries EGE; Hagemann UB; Lub-de Hooge MN
J Nucl Med; 2022 Nov; 63(11):1715-1721. PubMed ID: 35422447
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
11. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
[TBL] [Abstract][Full Text] [Related]
12. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E; Chauchet X; Richard F; Barba L; Moine V; Chatel L; Broyer L; Pontini G; Bautzova T; Juan F; Calloud S; Bosson N; Charreton M; Masternak K; Buatois V; Shang L
MAbs; 2020; 12(1):1739408. PubMed ID: 32191151
[TBL] [Abstract][Full Text] [Related]
13. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
14. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
15. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
19. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
